Becton, Dickinson and Company $BDX Stock: Vest Financial LLC Boosts Position

Vest Financial LLC increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 14.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 356,140 shares of the medical instruments supplier’s stock after acquiring an additional 46,239 shares during the period. Vest Financial LLC’s holdings in Becton, Dickinson and Company were worth $63,749,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Magnus Financial Group LLC acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth $250,000. Trifecta Capital Advisors LLC increased its holdings in shares of Becton, Dickinson and Company by 59.0% in the 3rd quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 62 shares in the last quarter. Axxcess Wealth Management LLC lifted its stake in shares of Becton, Dickinson and Company by 27.7% in the third quarter. Axxcess Wealth Management LLC now owns 8,516 shares of the medical instruments supplier’s stock valued at $1,524,000 after purchasing an additional 1,849 shares during the period. Inlet Private Wealth LLC lifted its stake in shares of Becton, Dickinson and Company by 5.0% in the third quarter. Inlet Private Wealth LLC now owns 29,180 shares of the medical instruments supplier’s stock valued at $5,223,000 after purchasing an additional 1,400 shares during the period. Finally, Strengthening Families & Communities LLC boosted its holdings in Becton, Dickinson and Company by 7.3% during the third quarter. Strengthening Families & Communities LLC now owns 16,520 shares of the medical instruments supplier’s stock worth $2,976,000 after buying an additional 1,122 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $194.29 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $195.99. The business’s fifty day moving average price is $184.73 and its two-hundred day moving average price is $164.54. The stock has a market cap of $53.53 billion, a PE ratio of 58.52, a price-to-earnings-growth ratio of 13.07 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the company earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

Wall Street Analysts Forecast Growth

BDX has been the topic of several recent analyst reports. UBS Group assumed coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price on the stock. Evercore set a $180.00 target price on Becton, Dickinson and Company in a report on Monday, July 6th. Stifel Nicolaus set a $195.00 price target on Becton, Dickinson and Company in a research report on Friday, August 7th. Citigroup reaffirmed a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Finally, Royal Bank Of Canada upped their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a report on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus price target of $185.07.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This trade represents a 14.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 6,906 shares of company stock worth $1,265,855. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.